Open Call for Funders & Translational Research Prospectus:
Launching the First Patient-Variant RORA Mouse Model
RORA Compass seeks $100,000 in catalytic philanthropic support to establish and phenotype the first patient-variant translational mouse model for RORA-related neurodevelopmental disorders. In partnership with leading translational experts, this 12-month initiative will generate validated in vivo data required to move from genetic discovery to therapeutic development. By creating this foundational research platform, the project positions the field for NIH-ready funding, industry engagement, and the first credible therapeutic pathway for affected children and families.
Executive Summary
Pathogenic variants in the RORA (Retinoic Acid Receptor–Related Orphan Receptor Alpha) gene are associated with rare neurodevelopmental disorders marked by developmental delay, motor dysfunction, intellectual disability, and behavioral differences. For families, diagnosis brings uncertainty rather than options. There are no disease-modifying therapies and no defined therapeutic program in development.
The barrier is not scientific rationale. RORA is a transcriptional regulator with broad influence over neuronal development and function, positioned at a biologically meaningful intersection of neurodevelopmental pathways. The case for therapeutic exploration is strong.
What is missing is the essential translational tool: a validated in vivo disease model. Without such a model, therapeutic hypotheses cannot be rigorously tested, biological rescue cannot be measured, and meaningful investment remains unlikely.
The Problem and Opportunity
The Initiative and Catalytic Investment
RORA Compass is launching a focused, milestone-driven preclinical program to establish and characterize a translationally actionable RORA variant mouse model.
We seek $100,000 to initiate this program immediately.
This investment will fund the generation of a precision RORA variant mouse colony, confirmation of genotype fidelity, comprehensive neurological and behavioral phenotyping, and the development of defined endpoints for therapeutic exploration. This is not exploratory science. It is a targeted infrastructure investment designed to enable intervention.
This investment does not fund a single experiment or publication. It creates a durable scientific asset — a reusable disease model that enables mechanistic discovery, therapeutic screening, and competitive federal funding. In rare disease research, the first validated model often catalyzes substantial follow-on support by reducing technical uncertainty and demonstrating translational readiness.
This is catalytic capital: it transforms RORA research from descriptive genetics into actionable therapeutic development.
The timing is strategic. Precision genome editing technologies are efficient and reliable. Established phenotyping infrastructure enables reproducible neurological and behavioral characterization. Translational rare disease expertise is in place. At the same time, philanthropic and biotech investment in monogenic neurodevelopmental disorders continues to accelerate.
The scientific tools exist. The partnerships are secured. What is required now is catalytic funding.
Why This Model Changes the Field
Within twelve months, we expect to have an established and genotyped RORA variant mouse colony, completed baseline neurological and behavioral phenotyping, defined measurable endpoints for therapeutic testing, and generated NIH-ready preliminary data. At that point, the central question shifts from “Can we model this disease?” to “Which therapeutic pathway should we pursue first?”
What Success Looks Like
Scientific oversight for this initiative will be led by a nationally recognized translational rare disease scientist with expertise in preclinical modeling and therapeutic development.
Model generation and phenotyping will be conducted in partnership with a premier U.S. biomedical research institution internationally recognized for precision mouse model development and standardized behavioral characterization.
RORA Compass will provide milestone-based reporting, budget transparency, and direct cost allocation. RORA Compass is a 501(c)(3) nonprofit organization dedicated specifically to advancing RORA-related research, and all funds will be deployed exclusively for the purposes described.
Governance and Accountability
Every rare disease field reaches a point when it moves from understanding to intervention. For RORA-related neurodevelopmental disorders, that moment is now. The science is ready. The partnerships are in place. The patient community is mobilized. The program is execution-ready. A $100,000 investment launches the first credible therapeutic pathway for RORA variants. We invite you to help create it.